Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your ...

WeightWatchers on Tuesday named Dr. Kim Boyd as chief medical officer and said it was planning a new program to help women ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Employees may be more prepared to embrace AI in the workplace than business leaders think.  “They are more familiar with AI ...

The decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” Direct access to Wegovy ® (semaglutide) will ...

Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding ...

Novo Nordisk (NVO) announced on Tuesday that it has submitted a new higher dose of its weight loss medication, Wegovy, to the European Medicines Agency for approval. The company is requesting approval ...

A high-level overview of Novo Nordisk A/S (NVO) stock. View (NVO) real-time stock price, chart, news, analysis, analyst reviews and more.